13 Oct. 2023
Foresee Pharmaceuticals Announces First Patient Dosed in the Casppian, Phase 3 Clinical Trial of Leuprolide (FP-001) injectable emulsion, 42 mg for the treatment of Central Precocious Puberty 
30 Sep. 2023
Foresee Pharmaceuticals to Present Phase 1/2 Fanconi Anemia Clinical Study Design for its ALDH2 activator FP-045 at the Fanconi Anemia Research Fund 2023 Scientific Symposium
29 Sep. 2023
Foresee Pharmaceuticals Announces Publication of Preclinical Data in Nature Communications Demonstrating the Therapeutic Potential of ALDH2 Activator AD-9308 in the Treatment of Obesity and Metabolic Syndrome-Related Disorders
11 Sep. 2023
Foresee Pharmaceuticals Presents Data From its Aderamastat Program at The European Respiratory Society (ERS) International Congress 2023
29 Aug. 2023
Foresee Pharmaceuticals Announces FDA Orange Book Listing of New U.S. Patent for CAMCEVI®, Extending Patent Protection to 2039
25 Jul. 2023
